Evogene (NASDAQ:EVGN) Releases Quarterly Earnings Results, Misses Expectations By $0.35 EPS

Evogene (NASDAQ:EVGN) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.35), FiscalAI reports. Evogene had a negative net margin of 214.57% and a negative return on equity of 117.04%. The business had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.28 million.

Here are the key takeaways from Evogene’s conference call:

• Management has sharply refocused Evogene on a single computational engine, ChemPass AI, and two target markets — small?molecule human therapeutics and agricultural chemicals — to concentrate resources and drive long?term value creation.
• ChemPass AI is presented as a differentiated generative platform built from a foundation model trained on a 38 billion molecules universe, and Evogene completed a first Google Cloud collaboration (90% design precision) with a second Vertex AI integration underway to automate discovery workflows.
• Management executed significant restructuring and portfolio moves — divesting non?core assets (Lavie Bio sale, MicroBoost AI), scaling down Biomica and Casterra, and integrating AgPlenus — which cut operating expenses to ~$13.8M in 2025 from ~$22M in 2024 and are expected to sustain lower expense levels.
• Despite cost cuts and a ~$6.4M gain on the Lavie Bio sale, revenues fell to ~$3.9M in 2025 (down ~$1.7M YoY), Casterra took an inventory impairment of ~$2.2 million, consolidated cash was ~$13 million at year?end (cash use Q4 ~ $3M) and management says runway is roughly 12–18 months without further transactions, though a Feb?2026 warrant exercise generated ~$3.4 million gross proceeds.

Evogene Stock Down 2.4%

Shares of EVGN stock traded down $0.02 on Friday, reaching $0.77. The company had a trading volume of 40,217 shares, compared to its average volume of 581,931. The stock has a market capitalization of $4.12 million, a PE ratio of -0.66 and a beta of 1.36. Evogene has a one year low of $0.73 and a one year high of $2.42. The business’s 50-day moving average is $1.00 and its 200 day moving average is $1.12.

Hedge Funds Weigh In On Evogene

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC boosted its holdings in Evogene by 58.0% during the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 12,387 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Evogene in the fourth quarter valued at about $25,000. Finally, Citadel Advisors LLC lifted its position in shares of Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 36,206 shares in the last quarter. 10.40% of the stock is currently owned by institutional investors.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.